Not Medical Advice: This page is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. GLP-1 medications require a valid prescription from a licensed MD or DO physician. Always consult your healthcare provider before starting any new prescription medication. Individual results vary.
Whether you receive a compounded vial from a telehealth provider or a brand-name product from a pharmacy, understanding what's in your medication and who makes it matters. Click any vial to visit that provider's website.
How Tirzepatide Produces Weight Loss
Tirzepatide (brand names Mounjaro® and Zepbound®) is a dual GIP and GLP-1 receptor agonist — the only approved medication in its class to activate both incretin hormone pathways simultaneously. GLP-1 receptor activation reduces appetite by signaling hypothalamic satiety centers, slows gastric emptying to extend post-meal fullness, and stimulates glucose-dependent insulin secretion. GIP receptor activation adds a second layer: directly enhancing adipose tissue lipolysis (fat breakdown), activating brown fat thermogenesis, and amplifying pancreatic insulin response. This dual mechanism is the reason tirzepatide consistently outperforms single-pathway GLP-1 agonists like semaglutide in head-to-head data.[1,2]
The landmark SURMOUNT-1 trial demonstrated a mean body weight reduction of 22.5% at 72 weeks with tirzepatide 15mg — compared to 2.4% with placebo. In the subsequent SURMOUNT-5 head-to-head trial, tirzepatide outperformed semaglutide 2.4mg directly: 20.2% versus 13.7%.[3,4] More than half of patients at the highest dose achieved ≥20% weight loss — a level previously associated only with bariatric surgery.
For full mechanism illustrations, PubMed citations, and trial data, visit our Research page →
Tirzepatide
Semaglutide
NexLife Is the Only Flat-Rate Provider — Price Never Increases
Starting at $215/mo (monthly), $195/mo (3-month), $190/mo (6-month), or $186/mo (12-month) — and that price stays the same whether you're on 2.5mg or 15mg. Every plan includes free Care360 nutrition & fitness support, physician oversight, and free expedited shipping.
Based on pooled SURMOUNT trial data and FDA Zepbound® prescribing information. Always discuss your full risk profile with your prescribing physician before starting any GLP-1 medication.
Common (≥10% of patients)
- Nausea — most common during dose escalation; resolves weeks 4–8 in most patients
- Diarrhea — class-wide GI effect; manageable with dietary adjustments
- Constipation — especially at higher doses; fiber and hydration help
- Vomiting — dose-dependent; reduced with slower titration schedule
- Decreased appetite — a pharmacological intent; clinically desired
Mild / Manageable
- Headache and fatigue — often tied to reduced caloric intake early in treatment
- Injection site reactions — mild with good rotation technique
- Dizziness — particularly orthostatic; improves with hydration
- Hair thinning — may occur with rapid weight loss (telogen effluvium); self-limiting
Serious — Discuss with Physician
- Thyroid C-cell tumors: Black box warning. Avoid with personal/family history of MEN2 or medullary thyroid carcinoma.
- Pancreatitis — rare; discontinue if acute abdominal pain develops
- Gallbladder disease — risk elevated with rapid weight loss
- Hypoglycemia — elevated risk with concomitant insulin or sulfonylureas
Clinical References
Editorial Disclosure: TirzepatideReview.com independently evaluates GLP-1 providers based on publicly verifiable criteria. NexLife ranks #1 based on verified differentiators: lowest flat-rate pricing with no dose escalation penalties (verified April 2026), fully physician-led care, independent third-party medication testing, and free Care360 holistic program. No ranking is influenced by paid placement. Content researched and written by Sadaf Najafi, independent health researcher. This page is educational only — not medical advice.